Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
The importance of the microenvironment in multiple myeloma
Results of trial of vadastuximab talirine plus hypomethylating agents in AML
Are combination therapies more effective for the treatment of relapsed refractory CLL?
The MUK Seven trial: tackling the issue of R/R multiple myeloma